A patent holder's request for a permanent injunction cannot be denied simply because removing an infringing drug from the market would reduce the number of available treatments, the federal appeals court ruled in a PCSK9 inhibitor patent dispute.
In an Oct. 5 opinion, a three-judge panel of the US Court of Appeals for the Federal Circuit unanimously...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?